dacetuzumab
mAbexperimental
Dacetuzumab is a humanized monoclonal antibody being developed for the treatment of CD40-positive cancers like non-Hodgkin's lymphoma and hematological malignancies. — Wikipedia
Clinical trial activity
9 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2004 (NCT00079716)
Timeline
Indications
Mechanism of action
CD40 inhibitor
Triggers antibody-dependent cell-mediated cytotoxicity. Mediates apoptosis.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDacetuzumab ↗
- ChEMBLCHEMBL1743005 ↗
Also known as
- dacetuzumab
- dacetuzumab
- dacetuzumab
- dacetuzumab
- hus2c6
- hu s2c6
- sgn 40
- sgn-40
- sgn-40
- sgn-40
- sgn-40
- sgn40 cpd
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00664898 | Phase 1 | May 1, 2008 | Genentech, Seattle Genetics |
| NCT00655837 | Phase 1 | Apr 1, 2008 | Genentech, Seattle Genetics |
| NCT00556699 | Phase 1 | Dec 1, 2007 | Genentech, Seattle Genetics |
| NCT00529503 | Phase 2 | Sep 1, 2007 | Genentech, Seattle Genetics |
| NCT00525447 | Phase 1 | Aug 1, 2007 | Genentech, Seattle Genetics |
| NCT00435916 | Phase 2 | Dec 1, 2006 | Genentech, Seattle Genetics |
| NCT00283101 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2005 | Genentech, Seattle Genetics |
| NCT00103779 | Phase 1 | Dec 1, 2004 | Genentech, Seattle Genetics |
| NCT00079716 | Phase 1 | Mar 1, 2004 | Genentech, Seattle Genetics |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genentech | For profit | 9 | 2 | 2 | 2004 |
| Seattle Genetics | For profit | 9 | 7 | 2 | 2004 |
2 organizations
Page 1 / 1